Core Viewpoint - The company has initiated a Phase I clinical trial for its self-developed candidate drug HX111, an OX40-targeted antibody-drug conjugate (ADC), aimed at treating relapsed/refractory lymphoma and solid tumors, with the first patient successfully dosed recently [1] Group 1: Drug Development - HX111 is designed to bind with high affinity and specificity to the OX40 molecule on the surface of tumor cells, facilitating efficient internalization and subsequent release of a potent payload that induces tumor cell apoptosis [1] - The OX40 molecule is highly expressed in certain lymphomas and solid tumors, which currently lack effective treatment options, indicating a significant unmet clinical need [1] - HX111 is the first OX40-targeted ADC drug to enter clinical trials globally, representing a first-in-class (FIC) innovation in this therapeutic area [1] Group 2: Market Opportunity - The field of OX40-targeted therapies is still in the early exploratory stage, providing HX111 with a significant first-mover advantage [1] - The development of HX111 has the potential to address a critical gap in the treatment landscape for these types of tumors [1]

Core Viewpoint - The company has initiated a Phase I clinical trial for its self-developed candidate drug HX111, an OX40-targeted antibody-drug conjugate (ADC), aimed at treating relapsed and refractory lymphoma and solid tumors, with the first patient successfully dosed recently [1] Group 1: Drug Development - HX111 specifically binds to the OX40 molecule on the surface of tumor cells with high affinity and specificity [1] - The drug efficiently enters tumor cells through endocytosis, where it is cleaved by lysosomal proteases to release a potent payload, inducing apoptosis in tumor cells [1] - OX40 is highly expressed in certain lymphomas and solid tumors, which currently lack effective treatment options, indicating a significant unmet clinical need [1] Group 2: Market Position - HX111 is the first OX40-targeted ADC drug to enter clinical trials globally, representing a first-in-class (FIC) innovation [1] - The field of OX40-targeted therapies is still in the early exploratory stage, giving HX111 a significant first-mover advantage [1] - The drug has the potential to fill a therapeutic gap in the treatment of these types of tumors in the future [1]

Core Viewpoint - The company has initiated a Phase I clinical trial for its self-developed candidate drug HX111, an OX40-targeted antibody-drug conjugate (ADC), aimed at treating relapsed/refractory lymphoma and solid tumors, with the first patient successfully dosed recently [1] Group 1: Drug Development - HX111 specifically binds to the OX40 molecule on the surface of tumor cells with high affinity and specificity [1] - The drug efficiently enters tumor cells through endocytosis, where it is cleaved by lysosomal proteases to release a potent payload, inducing tumor cell apoptosis [1] - OX40 is highly expressed in certain lymphomas and solid tumors, which currently lack effective treatment options, indicating a significant unmet clinical need [1] Group 2: Market Position - HX111 is the first OX40-targeted ADC drug to enter clinical trials globally, marking it as a first-in-class (FIC) product [1] - The field of OX40-targeted therapies is still in the early exploratory stage, providing HX111 with a significant first-mover advantage [1] - The drug has the potential to fill a therapeutic gap in the treatment of these types of tumors [1]